Thursday, 18 Aug 2011 08:00pm EDT
Shenzhen Hepalink Pharma. Co., Ltd. (002399.SZ )announced that it will invest RMB 20 million to set up a joint venture with Dr. Liu Liping, with each to hold a 57.143% and a 42.857% stake. The joint venture will be with a registered capital of RMB 35 million and be engaged in the research and development of polypeptide drugs.
Source:Reuters
Welcome to our website. This service is open to member only.
Contact our customer service team
Tel: 86-10-82600828, 82601561
Email: report@researchinchina.com